The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...
The FDA has approved Hympavzi to prevent bleeding episodes in hemophilia A and B patients aged 12 and older. This innovative ...
The FDA has approved Pfizer’s marstacimab (Hympavzi ... under FDA review is Sanofi’s fitusiran. This siRNA-based drug knocks down levels of the anticoagulant antithrombin, potentially ...
Last month, the US Food and Drug Administration ... The agency also approved Hympavzi (marstacimab, Pfizer) as routine ...
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...
Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...
As October draws to a close, it's time to take a look at the regulatory news that made headlines in the month and look ahead to ...
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...
Pfizer's Abrysvo is FDA-approved to prevent RSV in adults 18-59 ... before facing generic competition for their top-selling drugs. In 2023, an average of 440,000 people per week received RSV ...
On Tuesday, the FDA approved ... For Pfizer and GSK, RSV vaccines are critical as they seek to build new revenue streams before facing generic competition for their top-selling drugs.